Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults

Clinical trial NCT06028347 · COMPLETED

Trial details

NCT number: NCT06028347
Sponsor: Seqirus
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Influenza, Human

Start date: 2023-10-05
Primary completion: 2024-10-13
Enrollment: 96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.